{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-216469","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2021-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.212171+00:00","generated_at":"2026-06-30T04:59:46.947859+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Catalyst Biosciences promotes Grant Blouse to CSO; CMO Howard Levy to retire Aug 15","bullets":["Grant Blouse promoted to Chief Scientific Officer from SVP Translational Research; base salary $414,000 annually.","Blouse eligible for annual performance-based bonus up to 40% of base salary.","CMO Howard Levy to retire effective Aug 15, 2021; will join Clinical Advisory Board for hemophilia programs.","Levy's retirement not due to any disagreement with the company or its management."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-216469","json":"https://secwatch.observer/filing/0001193125-21-216469.json","markdown":"https://secwatch.observer/filing/0001193125-21-216469.md","text":"https://secwatch.observer/filing/0001193125-21-216469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521216469/0001193125-21-216469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521216469/d125524d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T04:59:46.947859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8334aeb829","claim":"Grant Blouse changed role as Chief Scientific Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On July 14, 2021, Catalyst Biosciences, Inc. (the “Company”) announced that Grant Blouse has been promoted to Chief Scientific Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521216469/0001193125-21-216469-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"e0b9f67487","claim":"Howard Levy retired as Chief Medical Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On July 14, 2021, the Company announced that Howard Levy, the Company’s Chief Medical Officer, plans to retire from his position.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521216469/0001193125-21-216469-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}